Publicaciones en las que colabora con Julen Oyarzabal Santamarina (108)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

2022

  1. CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage

    Thrombosis and Haemostasis, Vol. 122, Núm. 8, pp. 1314-1325

2021

  1. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with in Vivo Efficacy in Multiple Myeloma

    Journal of Medicinal Chemistry, Vol. 64, Núm. 6, pp. 3392-3426

  2. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  3. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

  4. Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis

    Gut, Vol. 70, Núm. 2, pp. 388-400

  5. Searching for peptide inhibitors of t regulatory cell activity by targeting specific domains of foxp3 transcription factor

    Biomedicines, Vol. 9, Núm. 2, pp. 1-20

  6. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

    Nature Communications, Vol. 12, Núm. 1

  7. mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 207-219

2020

  1. 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis

    Journal of medicinal chemistry, Vol. 63, Núm. 17, pp. 9237-9257

  2. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity

    Cancer Letters, Vol. 468, pp. 1-13

  3. Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis

    Cancers, Vol. 12, Núm. 12, pp. 1-27

  4. Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression

    Journal of Urology

  5. Towards the understanding of the activity of G9a inhibitors: an activity landscape and molecular modeling approach

    Journal of Computer-Aided Molecular Design, Vol. 34, Núm. 6, pp. 659-669

2019

  1. Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class i Histone Deacetylase Selective Inhibitors

    ACS Chemical Neuroscience, Vol. 10, Núm. 3, pp. 1765-1782

  2. Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors

    European Journal of Medicinal Chemistry, Vol. 168, pp. 87-109

  3. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma

    Hepatology, Vol. 69, Núm. 2, pp. 587-603

  4. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Nature Medicine